Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750941 · ClinicalTrials.gov registry record · Phase 2
Study of Copanlisib and Ketogenic Diet
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04750941 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1 participants.
The verdict
NCT04750941, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).
Interventions
- OTHER Ketogenic Diet
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04750941
The ClinicalTrials.gov registry entry for NCT04750941 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketogenic Diet is the first listed.
NCT04750941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04750941 about?
NCT04750941 is a clinical study titled "Study of Copanlisib and Ketogenic Diet". This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documen...
What is the current status of trial NCT04750941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-02-10. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT04750941?
The interventions under investigation include: Ketogenic Diet (OTHER), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT04750941?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.